Morningstar

OrbusNeich Medical Group Holdings Ltd 06929

Morningstar Rating
Unlock
Stock XHKG Rating as of
HK$4.00 +0.03 (0.76%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Chinese Endovascular Device Maker OrbusNeich Has Global Reach

Yurou Zheng

OrbusNeich differentiates itself as a specialist global medical device maker, producing percutaneous coronary intervention, or PCI, and percutaneous transluminal angioplasty, or PTA, devices. These are more commonly known as stents and balloons. Minimally invasive procedures such as PCIs are preferred novel treatments when treating cardiovascular diseases. Compared with traditional chest-opening procedures, OrbusNeich’s products are less traumatic and have less hospitalization time. Hence, we believe OrbusNeich can enjoy secular growth for the next five to 10 years.

Read Full Report

Price vs Fair Value

View History
06929 is trading within a range we consider fairly valued.
Price
HK$4.00
Fair Value
HK$5.57
Uncertainty
Very High
1-Star Price
HK$53.17
5-Star Price
HK$1.58
Economic Moat
Mqpj
Capital Allocation
Zvthhgb

Bulls Say, Bears Say

Bulls

Due to the increasing number of cardiovascular diseases, OrbusNeich may grow at an annual compounded rate of high teens for the next five to 10 years.

Bears

Geopolitical tensions escalate such that there may be more tax imposed on OrbusNeich products when sold in the US.

Show More

Trading Information

Previous Close Price
HK$3.97
Day Range
HK$3.97–4.00
52-Week Range
HK$2.86–9.52
Bid/Ask
HK$4.00 / HK$4.02
Market Cap
HK$3.30 Bil
Volume/Avg
230,500 / 120,476

Key Statistics

Price/Earnings (Normalized)
10.22
Price/Sales
2.81
Dividend Yield (Trailing)
2.50%
Dividend Yield (Forward)
2.50%
Total Yield
2.86%

Company Profile

OrbusNeich is a China-based global medical device maker of endovascular interventional instruments with global reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich’s largest revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its largest product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Small Value
Total Number of Employees
1,278
Website
https://www.orbusneich.com

Competitors

Valuation

View More
Metric
06929
BSX
ABT
Price/Earnings (Normalized)
 10.2237.5925.22
Price/Book Value
 1.136.054.97
Price/Sales
 2.818.144.82
Price/Cash Flow
 22.7531.4318.28
Price/Earnings
06929
BSX
ABT

Financial Strength

Metric
06929
BSX
ABT
Quick Ratio
 8.320.951.18
Current Ratio
 9.681.611.68
Interest Coverage
 154.668.6611.17
Quick Ratio
06929
BSX
ABT

Profitability

Metric
06929
BSX
ABT
Return on Assets (Normalized)
 9.80%9.33%10.75%
Return on Equity (Normalized)
 10.80%17.03%20.45%
Return on Invested Capital (Normalized)
 7.56%11.85%14.91%
Return on Assets
06929
BSX
ABT

Medical Instruments & Supplies Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
GzwbysyynyCbpb$170.4 Bil
 Becton Dickinson & Co
BDX
DwnrrpdCgxjdr$68.6 Bil
 Alcon Inc
ALC
TrhrncmmWxpqrbh$48.7 Bil
 ResMed Inc
RMD
VnmxbgxnWtcnl$35.0 Bil
 Coloplast AS ADR
CLPBY
VqgsgpbdjrTlz$29.2 Bil
 West Pharmaceutical Services Inc
WST
LdgmrmnhRpv$21.6 Bil
 The Cooper Companies Inc
COO
MzgbnhzRczjxdj$21.3 Bil
 Hologic Inc
HOLX
MftswrlqrXxtgq$18.4 Bil
 Baxter International Inc
BAX
NvkptlgBnhygv$17.9 Bil
 Align Technology Inc
ALGN
NrcsxpfmRxyfzl$17.7 Bil

Sponsor Center